GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of Françoise de Craecker to its Board of Directors, replacing Natalie Mount. Mrs. de Craecker is joining as an independent Director. “I am thrilled to be joining the GenSight team as they are transforming from an R&D company to a commercial organization with LUMEVOQ, their lead product for the treatment of LHON, being rev...
Source: biospace.com